Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The aldosterone blocking effects of spirolactones.

Literature DB >> 13887873

The aldosterone blocking effects of spirolactones.

V A DRILL.

Abstract

Entities: Chemical

Keywords: ALDOSTERONE/antagonists

Mesh：

Substances：

Year: 1962 PMID： 13887873 DOI： 10.1254/jjp.11.77

Source DB: PubMed Journal: Jpn J Pharmacol ISSN： 0021-5198

Keyword Cloud
Cited

× No keyword cloud information.

8 in total

1. Bioassay of aldosterone antagonists in normal human subjects: a relationship between the level of plasma uric acid before treatment and apparent drug responses.

Authors: L E Ramsay; P Hessian; M J Tidd
Journal: Br J Clin Pharmacol Date: 1975-06 Impact factor: 4.335

2. Canrenone--the principal active metabolite of spironolactone?

Authors: L E Ramsay; J R Shelton; D Wilkinson; M J Tidd
Journal: Br J Clin Pharmacol Date: 1976-08 Impact factor: 4.335

3. Quantitative comparison of aldosterone antagonists in normal human subjects: prediction of therapeutic potency.

Authors: G T McInnes; I R Harrison; J R Shelton; R M Perkins
Journal: Br J Clin Pharmacol Date: 1981-11 Impact factor: 4.335

4. Proceeding of the British Pharmacological Society, Clinical Pharmacology Section, 16-18th December, 1980, University of London. Abstracts.

Authors:
Journal: Br J Clin Pharmacol Date: 1981-04 Impact factor: 4.335

5. Relative potency and structure activity relationships of aldosterone antagonists in healthy man: correlation with animal experience.

Authors: G T McInnes; J R Shelton; L E Ramsay; I R Harrison; M J Asbury; J M Clarke; R M Perkins; G R Venning
Journal: Br J Clin Pharmacol Date: 1982-03 Impact factor: 4.335

The aldosterone blocking effects of spirolactones.

1. Bioassay of aldosterone antagonists in normal human subjects: a relationship between the level of plasma uric acid before treatment and apparent drug responses.

2. Canrenone--the principal active metabolite of spironolactone?

3. Quantitative comparison of aldosterone antagonists in normal human subjects: prediction of therapeutic potency.

4. Proceeding of the British Pharmacological Society, Clinical Pharmacology Section, 16-18th December, 1980, University of London. Abstracts.

5. Relative potency and structure activity relationships of aldosterone antagonists in healthy man: correlation with animal experience.

6. Spironolactone dose-response relationships in healthy subjects.

7. Antagonism of endogenous mineralocorticoids in normal subjects by prorenoate potassium and spironolactone.

8. The interaction of canrenone with oestrogen and progesterone receptors in human uterine cytosol.